SCHEMBL4512919

SCHEMBL4512919

O=C(O)Cc1nc(-c2ccc(C(F)(F)F)cc2)cs1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.62
L3MBTL1 Q9Y468 5/20 0.62
HDAC3 O15379 1/20 0.58
HDAC4 P56524 1/20 0.58
HDAC1 Q13547 1/20 0.58
HDAC7 Q8WUI4 1/20 0.58
HDAC2 Q92769 1/20 0.58
HDAC10 Q969S8 1/20 0.58
HDAC11 Q96DB2 1/20 0.58
HDAC8 Q9BY41 1/20 0.58
HDAC6 Q9UBN7 1/20 0.58
HDAC9 Q9UKV0 1/20 0.58
HDAC5 Q9UQL6 1/20 0.58
PPARD Q03181 1/20 0.54
LMNA P02545 2/20 0.51
RAB9A P51151 2/20 0.51
LTA4H P09960 1/20 0.51
GSTO1 P78417 1/20 0.51
HPSE Q9Y251 1/20 0.51
MEN1 O00255 4/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL201719 0.82 L3MBTL1 (0.60) ALDH1A1L3MBTL1HDAC3HDAC4HDAC1
SCHEMBL2852600 0.82 L3MBTL1 (0.64) ALDH1A1L3MBTL1HDAC3HDAC4HDAC1
SCHEMBL1795513 0.82 ALDH1A1 (0.67) ALDH1A1L3MBTL1HDAC3HDAC4HDAC1
SCHEMBL628637 0.81 RXRA (0.53) ALDH1A1L3MBTL1HDAC3HDAC4HDAC1
SCHEMBL13731307 0.81 ALDH1A1 (0.67) ALDH1A1L3MBTL1PPARDLMNARAB9A
SCHEMBL4190251 0.79 HDAC1 (0.60) ALDH1A1L3MBTL1HDAC3HDAC4HDAC1
SCHEMBL1199271 0.79 LTA4H (0.57) ALDH1A1L3MBTL1HDAC3HDAC4HDAC1
SCHEMBL28708808 0.79 LTA4H (0.57) ALDH1A1L3MBTL1HDAC3HDAC4HDAC1
SCHEMBL16964440 0.79 MAPT (0.54) ALDH1A1L3MBTL1LMNARAB9AHPSE
SCHEMBL204739 0.79 L3MBTL1 (0.56) ALDH1A1L3MBTL1HDAC3HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090012097-A1 Polycyclic 1,2,3,4-Tetrahydro-Isoquinoline Derivatives and Compositions Comprising Them As Ppar Modulators IRM LLC (BM) 2009-01-08 US disclosed
US-20090012097-A1 Polycyclic 1,2,3,4-Tetrahydro-Isoquinoline Derivatives and Compositions Comprising Them As Ppar Modulators IRM LLC (BM) 2009-01-08 US disclosed
US-20090012097-A1 Polycyclic 1,2,3,4-Tetrahydro-Isoquinoline Derivatives and Compositions Comprising Them As Ppar Modulators IRM LLC (BM) 2009-01-08 US disclosed
EP-1979347-A2 POLYCYCLIC 1,2,3,4-TETRAHYDRO-ISOQUINOLINE DERIVATIVES AND COMPOSITIONS COMPRISING THEM AS PPAR MODULATORS IRM LLC (BM) 2008-10-15 EP disclosed
WO-2007089557-A2 POLYCYCLIC 1, 2, 3, 4 -TETRAHYDRO- ISOQUINOLINE DERIVATIVES AND COMPOSITIONS COMPRISING THEM AS PPAR MODULATORS IRM LLC (BM) 2007-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012097-A1 Polycyclic 1,2,3,4-Tetrahydro-Isoquinoline Derivatives and Compositions Comprising Them As Ppar Modulators PPARG, PPARD, PPARA ALDH1A1 1446/4885L3MBTL1 4441/4885HDAC3 35/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.